Ignite Creation Date:
2024-05-06 @ 6:48 PM
Last Modification Date:
2024-10-26 @ 2:54 PM
Study NCT ID:
NCT05780684
Status:
RECRUITING
Last Update Posted:
2023-07-17
First Post:
2023-03-10
Brief Title:
Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer
Sponsor:
Dartmouth-Hitchcock Medical Center
Organization:
Dartmouth-Hitchcock Medical Center
Study Overview
Official Title:
Adaptive Individualized Dose Escalation of Fluorouracil-Based Chemotherapy for Gastrointestinal Cancer Pilot Study of the FOX Regimen
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FOXRegimen
Brief Summary:
This is a single-arm clinical trial to evaluate the feasibility of a chemotherapy regimen using adaptive individualized dose escalation of 5-FU chemotherapy for patients who have good tolerance of the initial dose Study participants will also receive oxaliplatin chemotherapy together with 5-FU at standard doses The goal of the study is to examine the feasibility and effectiveness of this approach using individualized dose escalation of 5-FU in patients who do not have serious side effects at lower doses
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 22BRO873 | OTHER | Dartmouth Health | None |